ENDO INTERNATIONAL PLC (NASDAQ:ENDP) Files An 8-K Other Events
Item 8.01Other Events.

Endo International plc (the Company) is filing this Current Report on Form 8-K to update the presentation of certain financial information and related disclosures included in the Company's Annual Report on Form 10-K for the year ended December 31, 2017, which was filed with the Securities and Exchange Commission (the SEC) on February 27, 2018 (the 2017 10-K).

In the 2017 10-K, theCompany's threereportable business segments were: (1)U.S. Generic Pharmaceuticals, (2)U.S. Branded Pharmaceuticalsand (3)International Pharmaceuticals. During the first quarter of 2018, the Company made changes to the way it manages and evaluates its business and, as a result, changed its reportable segments. The Company's Sterile Injectables product portfolio, which was part of the U.S. Generic Pharmaceuticals segment as of December 31, 2017, will now be presented as a new segment named “U.S. Branded – Sterile Injectables.” Additionally, the Company's U.S. Branded Pharmaceuticals segment has been renamed “U.S. Branded – Specialty & Established Pharmaceuticals.” Subsequent to this change, the Company's four reportable business segments are: (1) U.S. Branded – Specialty & Established Pharmaceuticals, (2)U.S. Branded – Sterile Injectables, (3)U.S. Generic Pharmaceuticals and (4) International Pharmaceuticals.

Exhibit 99.1 to this Current Report on Form 8-K contains the following items from the 2017 10-K, which have been updated as described below to reflect the foregoing segment changes, consistent with the presentation included in the Company's Quarterly Report on Form 10-Q for the three months ended March 31, 2018, which was filed with the SEC on May 8, 2018:

The information in this Current Report on Form 8-K (including Exhibit 99.1 hereto) supersedes what was in the 2017 10-K. Other information from the 2017 10-K is not being updated in connection with this Current Report on Form 8-K.

This information has been revised only as described above and has not been updated for events occurring after the filing of the 2017 10-K. Accordingly, this Current Report on Form 8-K does not purport to update the amounts or disclosures for any information, uncertainties, transactions, risks, events or trends occurring, or known to management, except as is related to the items described above. For other developments since the filing of the 2017 10-K, refer to the Company's Quarterly Report on Form 10-Q for the three months ended March 31, 2018 (the First Quarter 2018 10-Q) and other filings made by the Company subsequent to the filing of the 2017 10-K. Therefore, the information in this Current Report on Form 8-K (including Exhibit 99.1 hereto) should be read in conjunction with the 2017 10-K and the Company's filings made subsequent to the filing of the 2017 10-K, including the First Quarter 2018 10-Q, in which retrospective application of the Company’s new segments was presented for the quarterly periods ended March 31, 2018 and 2017.

Item 9.01.Financial Statements and Exhibits.

Endo International plc Exhibit
EX-23.1 2 ex231consentofpwcllp123120.htm EXHIBIT 23.1 Ex 23.1 Consent Exhibit 23.1CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRMWe hereby consent to the incorporation by reference in the Registration Statements on Form S‑8 (No. 333-194253,…
To view the full exhibit click here